Articles for Healthcare Cost & Expenditures
January 17, 2017 | Patricia J. Zettler, JD, and Erin C. Fuse Brown, JD, MPH
For cost-effective cures, the drug pricing policy challenge is not simply to lower prices, but also to spread the drug costs among payers.
January 17, 2017 | Jennifer Karweit, MS; Srividya Kotapati, PharmD; Samuel Wagner, PhD; James W. Shaw, PhD, PharmD, MPH; Steffan W. Wolfe, BA; and Amy P. Abernethy, MD, PhD
A novel, simplified cost-value analysis tool was created to better differentiate the value of anticancer agents and further characterize the expected survival benefit of all patients.
January 16, 2017 |
Rena M. Conti, PhD; Brenton Fargnoli, MD; and Andrew L. Pecora, MD, CPE, discuss concerns regarding the use of newer therapies, specifically immuno-oncology agents, for the treatment of cancer. Among their considerations, they remark on the financial burden these agents place on various stakeholders and consider who should be responsible for treatment coverage.
January 16, 2017 | Surabhi Dangi-Garimella, PhD
An experiment by Park Nicollet Health Services to document personalized pain management goals for patients in oncology clinics lowered documented pain, while physician education on cost information helped reduce treatment costs.
January 15, 2017 |
Bundled payment models could provide surgeons with a full spectrum of data that can help them decide which hospital is the right choice for their patients, said Andrei Gonzales, MD, McKesson's director of value-based reimbursement initiatives. He also said that this data can drive improvement for hospitals that may be falling behind.
January 14, 2017 |
Payers have been slow to adopt new technologies, but they are starting to be more proactive in seeking out genomic profiling companies, according to David Fabrizio, of Foundation Medicine, Inc. These molecular diagnostic tools make the healthcare process more efficient by performing a comprehensive test at the point of diagnosis.
January 13, 2017 |
This week, the top stories in managed care were that the Senate began the process of repealing the Affordable Care Act, Cigna and CVS moved away from the EpiPen, and the NCI Formulary will make it easier to study cancer drugs and their combinations.
January 13, 2017 | Surabhi Dangi-Garimella, PhD
The American Society of Clinical Oncology (ASCO) hopes that the principles will help ensure access to healthcare and adequate insurance, to improve outcomes among those diagnosed with cancer.